Phathom Pharmaceuticals Faces Investor Probe After Lowering Revenue Targets
Florham Park, Tuesday, 4 August 2026.
Phathom Pharmaceuticals is facing shareholder law investigations after cutting its 2026 revenue forecast to $310–325 million, sparking a 22% stock selloff and allegations of misleading investors.
Revenue Guidance and Market Reaction
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) announced a revision to its full-year 2026 net revenue guidance on August 1, 2026, lowering the forecast to a range of $310 million to $325 million [3]. This updated outlook falls below the company’s previous guidance range of $320 million to $345 million, representing a contraction in the high-end estimate of -5.797 percent [1][3]. The revised figures also missed Wall Street consensus estimates, which had projected revenue between $332 million and $334 million [1][4]. Following the announcement, Phathom Pharmaceuticals shares fell 22% on July 30, 2026, marking the stock’s worst day in over 1.5 years [2]. Year-to-date as of July 29, 2026, the stock had already declined 46% prior to this latest development [2].
The revenue shortfall raises questions regarding the commercial rollout of the company’s gastrointestinal treatments, specifically VOQUEZNA (vonoprazan) [4]. Prior to the guidance reduction, the company had reported having more than 290 representatives in place to start the second quarter and had projected a path to $1 billion in annual revenue from gastroenterology prescriptions [4][5]. The discrepancy between earlier optimistic projections and the current revised guidance forms the basis of the current investor concern [1].
Legal Investigations Intensify
In response to the guidance reduction and subsequent share price decline, law firm Levi & Korsinsky, LLP announced an investigation into potential securities law violations on August 3, 2026 [4]. The firm is examining whether Phathom Pharmaceuticals made materially false or misleading statements regarding its fiscal year 2026 revenue outlook [1]. Concurrently, Bronstein, Gewirtz & Grossman, LLC initiated a separate investigation into potential claims on behalf of purchasers of Phathom securities on August 2, 2026 [3]. Both firms are focusing on whether the company failed to disclose information pertinent to investors or issued misleading statements during the class period [3][5].
Levi & Korsinsky, LLP is ranked in the ISS Top 50 for seven consecutive years and is soliciting investors who purchased PHAT stock and suffered losses to evaluate potential claims [1]. The investigation concerns the period during which the company reaffirmed its higher revenue guidance, specifically noting statements made during the February 26, 2026, and April 30, 2026, earnings calls [3]. During the April 30, 2026, call, company leadership stated they were maintaining their revenue guidance for the year, a statement now under scrutiny [3].
Commercial Context and Investor Recourse
Despite the guidance cut, Phathom Pharmaceuticals reported record net revenue of $74.3 million in the second quarter ended June 30, 2026, an 88% increase from $39.5 million a year earlier [2]. As of the second quarter of 2026, the company reported $182.5 million in cash and equivalents and achieved its first operating profitability excluding stock-based compensation [2]. Enrollment for the 95-patient pHalcon-EoE-201 trial concluded in June 2026, with topline results projected for the fourth quarter of 2026 [2].
Investors who purchased PHAT securities and suffered losses are advised to gather brokerage records, including purchase dates, share quantities, and prices paid [1][5]. Participation in the investigations requires no upfront costs or retainer fees, as these matters are handled on a contingency basis [1]. Interested parties may contact Levi & Korsinsky, LLP via email or phone, or visit the firm’s website for a no-cost evaluation [1][3]. Eligibility is determined by the purchase period rather than current share retention, meaning investors who have already sold their shares at a loss remain eligible to participate [1].